Home https://server7.kproxy.com/servlet/redirect.srv/sruj/smyrwpoii/p2/ Health https://server7.kproxy.com/servlet/redirect.srv/sruj/smyrwpoii/p2/ COVID SCIENCE-Antibody neutralizes virus variants in a laboratory study; COVID-19 antibodies detectable 12 months after infection

COVID SCIENCE-Antibody neutralizes virus variants in a laboratory study; COVID-19 antibodies detectable 12 months after infection



By Nancy Lapid

May 3 (Reuters) – An overview of some of the latest research on the new coronavirus and efforts to find treatments and vaccines for COVID-19, the disease caused by the virus, follows.

An experimental antibody drug neutralized COVID-19 variants

Experimental treatment with monoclonal antibodies against COVID-19, developed by Eli Lilly and Co and AbCellera Biologics Inc, can “powerfully” neutralize many variants of coronavirus, including those first identified in the UK, Brazil, South Africa, California and New York. York, scientists have found in experiments with test tubes. The antibody ̵

1; known as LY-CoV1404 or LY3853113 – works by attaching to the site of the virus, showing little signs of mutation, meaning the drug is likely to remain effective over time, researchers said in a report released Friday of bioRxiv before peer review. “New variations resistant to variants such as LY-CoV1404 are essential, as some of the existing therapeutic antibodies are less effective or ineffective against certain variants and the impact of variants on vaccine efficacy is still poorly understood. “, Writes the research team. A spokesman for AbCellera said the company plans to release information about drug trials in humans on Tuesday. (https://bit.ly/3gYQnAU)

Antibodies to COVID-19 are still detected at 12 months

Some COVID-19 survivors infected at the start of the pandemic still have detectable antibodies to the virus a year later, according to a new study. U.S. doctors collected blood samples from 250 patients, including 58 who were hospitalized for COVID-19 and 192 who did not need to be hospitalized. Six to 10 months after diagnosis, all former inpatients and 95% of outpatients still had neutralizing antibodies, according to a report published Sunday by medRxiv before a peer review. In the small subset of year-round follow-up, 8 of the 8 people who were hospitalized still had antibodies, as did 9 of the 11 former outpatients. Antibody levels during follow-up were related to age and severity of COVID-19. Older age was associated with higher levels of neutralizing antibodies, while levels were “lower and more variable” in participants under 65 years of age who experienced less severe COVID-19 and did not need from hospitalization, the researchers said. They said vaccinating COVID-19 survivors “would be reasonable” because vaccine-induced protection against the virus is likely to be longer lasting than antibodies induced by the drug COVID-19. (https://bit.ly/3eelS82)

No association was seen between COVID-19 and aspirin or ibuprofen

A large new study found no indication that the use of nonsteroidal anti-inflammatory drugs (NSAIDs) such as aspirin or ibuprofen increased people’s vulnerability to infection with the new coronavirus. Because early reports suggest such a link, the researchers used the COVID Symptom Study smartphone app to ask more than 2.7 million people in the United States, Britain and Sweden about their use of aspirin and other NSAIDs, as well as the symptoms of the virus. COVID -19 testing and behavior seeking healthcare. Nearly 9,000 participants reported a positive COVID-19 test during the study, according to a report published Sunday at medRxiv before a peer review. After considering the lifestyle factors of individuals, other diseases and symptoms, regular use of NSAIDs is not associated with a higher risk of coronavirus infection. “There are long-standing concerns that ‘frequently used NSAIDs’ may increase the risk of COVID infection or worsen the course of the disease among those who become infected,” said co-author Dr. Andrew Chan of Boston Massachusetts Hospital. “Our study shows that there is no such link, and initial concerns are likely due to the fact that people with other risk factors for COVID or COVID symptoms are more likely to take NSAIDs than a causal link,” he said. (https://bit.ly/3vzKNZN)

Open https://tmsnrt.rs/3c7R3Bl in an external browser for the Reuters schedule for vaccines under development.

(Report by Nancy Lapid; Edited by Bill Bercrot)


Source link